This study is a prospective, randomized pilot study. To verify an efficacy/safety of the mixed drug injectable delivery vehicle for treating intractable hearing loss. Hearing test, endoscopy of tympanic membrane and CT scans will be conducted after intratympanic treatment for evaluation.

开始日期2026-12-15

申办/合作机构

Seoul National University Hospital

NCT04366115

/ Not yet recruiting临床1期

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study Evaluating AVM0703 in Patients With Acute Respiratory Distress Syndrome

This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 or influenza (A or B). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose of AVM0703 in these ARDS patients.

开始日期2026-12-01

申办/合作机构

AVM Biotechnology LLC

[+1]

NCT07636564

/ Not yet recruiting临床2期IIT

A Phase II Randomized Study of Blinatumomab With or Without Revumenib for Patients With KMT2A-Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia With Ambiguous Lineage (ALAL) With Persistent Measurable Residual Disease (MRD)

This phase II trial tests how well adding revumenib to usual treatment (blinatumomab) compared to usual treatment alone works in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) or acute leukemia with ambiguous lineage (ALAL) with KMT2A-translocation. Revumenib binds to a protein called menin and keeps it from binding to another protein called KMT2A. This stops or slows the growth of leukemia cells with changes in the KMT2A gene. Blinatumomab binds to CD19, which is found on most B cells (a type of white blood cell) and some types of leukemia cells. It also binds to a protein called CD3, which is found on T cells (another type of white blood cell). This may help the immune system kill cancer cells. In addition to blinatumomab, usual treatment also includes dexamethasone, methotrexate, cyclophosphamide, cytarabine, mercaptopurine, calaspargase pegol, doxorubicin, thioguanine, daunorubicin, vincristine and leucovorin. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Chemotherapy drugs, such as cytarabine, mercaptopurine, calaspargase pegol, doxorubicin, thioguanine, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Leucovorin is also being studied in the treatment of cancer. It is a type of chemoprotective agent and a type of chemosensitizing agent. Adding revumenib to usual treatment with blinatumomab may be safe, tolerable and more effective than blinatumomab alone in lowering the amount of leukemia in patients with B-ALL or ALAL with the KMT2A translocation.

开始日期2026-10-14

申办/合作机构

SWOG

[+1]

100 项与地塞米松磷酸钠相关的临床结果

登录后查看更多信息

100 项与地塞米松磷酸钠相关的转化医学

登录后查看更多信息

100 项与地塞米松磷酸钠相关的专利（医药）

登录后查看更多信息

1,519

项与地塞米松磷酸钠相关的文献（医药）

2026-07-01·VETERINARY ANAESTHESIA AND ANALGESIA

Novel ultrasound-guided flags assisted WalKing block for enhanced recovery after surgery (FAWKES) in three dogs undergoing tibial plateau levelling osteotomy

Article

作者: Le, Stephanie ; Gingold, Benjamin Mc ; Milloway, Matthew C

This case series describes a novel, regional anesthesia technique in three dogs of various breeds, aged 2.5, 8, and 10 years old, weighing 42.6, 32.6, and 13.4 kg, respectively, presenting for tibial plateau levelling osteotomy. Physical examination was unremarkable aside from evidence of a ruptured cranial cruciate ligament. After anesthetic premedication and induction of general anesthesia, the affected limb was aseptically prepared. A combination of regional nerve blocks was performed, including the inFiLtrating Around Genicular Structures (FLAGS) block, saphenous block, and periarticular knee infiltration; together, termed the Flags Assisted WalKing block for Enhanced recovery after Surgery (FAWKES). A mixture of 0.5% ropivacaine (4 mg kg^-1), dexmedetomidine (1.6 ug kg^-1), dexamethasone sodium phosphate (0.004 mg kg^-1), and epinephrine (4 ug kg^-1) was used for the FLAGS (0.2 mL kg^-1), saphenous (0.1 mL kg^-1), and periarticular knee infiltration (0.125 mL kg^-1 per site; four sites). There were no increases in heart rate, respiratory rate, or mean arterial blood pressure greater than 20% from surgical start time to end time, aside from expected elevations following administration of anticholinergics or vasopressors. All dogs retained motor function postoperatively. Two of the three dogs ambulated on the operated limb within one hour of recovery. The third was nonweight-bearing but able to flex the stifle and elevate the limb. One dog was given a single postoperative dose of intravenous methadone (0.2 mg kg^-1) 12 hours after surgery, whereas the remaining dogs required no rescue analgesia. All dogs ate within 12 hours of surgery and were discharged without complications. These findings suggest that the described multimodal analgesic plan, including the FAWKES block, provided adequate intraoperative analgesia while preserving motor function postoperatively. Controlled studies are required to evaluate the efficacy and safety of the FAWKES block, along with more detailed anatomical investigations of the canine stifle joint.

2026-06-01·AMERICAN JOURNAL OF VETERINARY RESEARCH

Repeated intravenous dexamethasone administration causes transient changes in leukocyte parameters in healthy warmblood horses

Article

作者: Vendrig, Johannes C. ; Roelfsema, Ellen ; Hendrikx, Anne L. ; Gehring, Ronette ; van Alphen, Jennifer ; van den Boom, Robin ; Teske, Erik ; Vernooij, Johannes C. M.

Abstract:

Objective:

To determine the effect of repeated IV administration of dexamethasone (0.06 mg/kg, q 24 h, twice) on WBC parameters in healthy adult horses.

Methods:

This prospective, longitudinal study was conducted from October 7 through November 5, 2024. Five warmblood mares received an IV dexamethasone sodium phosphate injection (DMI) at 0 and 24 hours and an IV injection with 0.9% sodium chloride solution at 48 and 72 hours. Blood samples were collected at 0, 6, 12, 24, 30, 36, 48, 72, 96, and 168 hours, and WBC parameters were evaluated using linear mixed-effects models.

Results:

Leukocyte count, neutrophil count, and neutrophil-to-lymphocyte ratio were increased at 6 hours after DMI. Mean leukocyte count peaked 6 hours after DMI and exceeded the reference interval; however, not all horses had peaks above the reference interval. Neutrophilia was observed in all horses, with peak values 6 hours after DMI. Lymphocyte, monocyte, and eosinophil counts were decreased at 6 hours after DMI, with complete suppression of eosinophils. Myeloperoxidase index was increased only at 6 hours after the second DMI. Neut-X was decreased at 12 hours after DMI, and Neut-Y did not change up to 156 hours after the first DMI. Most parameters returned to baseline at 48 to 72 hours.

Conclusions:

Repeated IV dexamethasone administration induces recognizable changes in leukograms in healthy horses with transient neutrophilia combined with increased leukocyte counts and neutrophil-to-lymphocyte ratios and decreased lymphocyte, monocyte, and eosinophil counts.

Clinical Relevance:

Recognition of glucocorticoid-induced changes is important for accurate interpretation of hematologic findings in horses receiving glucocorticoids.

2026-04-20·Cureus Journal of Medical Science

Dexamethasone Iontophoresis for Musculoskeletal Tendinopathies: A Case Series of Three Patients

Article

作者: Ikhilov, Rachel B ; Kharlamb, Lily ; Gitlin-Nitti, Yevgenia J

Iontophoresis is a non-invasive transdermal drug delivery technique that uses low-voltage electric current to deliver ionized medications into soft tissues. Despite guideline recommendations supporting dexamethasone iontophoresis for tendinopathies, the existing evidence consists primarily of condition-specific randomized controlled trials and single-site retrospective studies, with no published case series illustrating the real-world application of dexamethasone iontophoresis across multiple tendinopathy types within a single report. This case series describes the outcomes of dexamethasone iontophoresis as part of multimodal physical therapy for three distinct tendinopathies. This retrospective case series included three patients treated at a Veterans Affairs physical therapy clinic with dexamethasone sodium phosphate (4 mg/mL) iontophoresis (40 mA-min per session) using the ActivaDose II system. While the small sample size limits generalizability, this series is intended to illustrate the real-world clinical application of dexamethasone iontophoresis across multiple tendinopathy types rather than to establish efficacy. Concurrent interventions included therapeutic exercise, patient education, and orthotic management. Outcomes assessed included pain (0-10 numeric scale), range of motion, grip strength, and Upper Extremity Functional Index (UEFI) scores. Case 1 (de Quervain's tenosynovitis) is a 47-year-old man with persistent, functionally limiting wrist pain who completed seven sessions over 24 days. Pain decreased from 3-4/10 to 1/10, grip strength improved from 60 to 75 lbs (equalizing with the uninvolved side), and UEFI improved by 8 points (exceeding the MCID). Case 2 (fluoroquinolone-associated Achilles tendinopathy) is a 56-year-old woman who completed six sessions over nine weeks. Pain decreased from 8/10 to 2-3/10, and ankle dorsiflexion improved from 7° to 16° (left) and 10° to 20° (right), surpassing the normative threshold of 10°. Case 3 (lateral epicondylitis) is a 62-year-old man with acute-onset symptoms who completed 12 sessions over six weeks. Pain decreased from 8/10 to 2-3/10, grip strength improved from 22 to 110 lbs (exceeding the uninvolved side of 80 lbs), and UEFI improved by 46 points (exceeding the MCID). No adverse effects were reported. Dexamethasone iontophoresis, as part of comprehensive physical therapy, was associated with clinically meaningful improvements in pain, strength, and function across three tendinopathy types. These findings suggest that dexamethasone iontophoresis may serve as a useful non-invasive adjunct in the multimodal management of musculoskeletal tendinopathies, though prospective controlled studies are needed to confirm its independent contribution.

603

项与地塞米松磷酸钠相关的新闻（医药）

2026-07-20

·ioncology

ESMO 2026丨瞭望前瞻，百余项中国乳腺癌研究亮相ESMO，一文速览

点击蓝字，关注我们编者按：2026年欧洲肿瘤内科学会年会（ESMO 2026）将于10月23日至27日在西班牙马德里召开。作为全球肿瘤领域最具影响力的年度盛会之一，ESMO每年覆盖基础研究、转化医学与临床诊疗全维度前沿进展，是国际肿瘤学界交流学术成果、更新诊疗理念的核心平台。目前，ESMO官网已公布部分摘要标题，《肿瘤瞭望》特针对乳腺癌领域的中国入选研究进行系统梳理，供读者提前把握本次大会的中国学术动态。（由于目前多数研究摘要全文尚未正式发布，本次整理仅基于已公开的标题信息，如有疏漏或表述偏差，敬请留言指正。）快速口头报告摘要号：4RO 英文标题：Target switching with conserved-payload novel ADCs in patients with metastatic breast cancer following prior ADC therapy (SWITCH): a prospective, open-label, phase 2 platform trial 中文标题：转移性乳腺癌ADC经治后采用同载荷异载荷新型ADC的靶点转换研究：一项前瞻性、开放标签的 II 期平台试验（SWITCH）讲者：刘西禹 (复旦大学附属肿瘤医院) 摘要号：5RO 英文标题：Safety and efficacy of SYS6043, a Novel B7-H3–Targeting Antibody-Drug Conjugate, in Patients with Advanced breast cancer 中文标题：新型靶向B7-H3 ADC SYS6043治疗晚期乳腺癌的安全性与有效性讲者：王红霞 (复旦大学附属肿瘤医院) 摘要号：4639RO 英文标题：Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01 中文标题：芦康沙妥珠单抗对比化疗用于既往经治局部复发或转移性三阴性乳腺癌的III期OptiTROP-Breast01研究最终OS分析讲者：樊英 (中国医学科学院肿瘤医院) 摘要号：4640RO 英文标题：Bulumtatug Fuvedotin (BFv, 9MW2821), a Nectin-4–Directed Antibody-Drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer (la/mTNBC) Previously Treated with Topoisomerase I Inhibitor (TopI)-Based ADCs: Results from a Phase 2 Study 中文标题：新型靶向Nectin-4 ADC bulumtatug Fuvedotin（BFv，9MW2821）在既往接受过拓扑异构酶I抑制剂为基础的ADC治疗的局部晚期或转移性三阴性乳腺癌（la/mTNBC）患者中显示出显著疗效：一项II期临床研究的结果讲者：张剑 (复旦大学附属肿瘤医院) 壁报 Basic science（基础科学）摘要号：399P 英文标题：C15orf48 drives breast cancer liver metastasis via glutathione dependent activation of Wnt/β-catenin signaling 中文标题：C15orf48通过谷胱甘肽依赖性激活Wnt/β-catenin信号通路驱动乳腺癌肝转移讲者：宋振川（河北医科大学第四医院） Advanced breast cancer, other（晚期乳腺癌，其他）摘要号：6P 英文标题：Machine learning model based on pathomics features predicts T-DXd response in advanced breast cancer 中文标题：基于病理组学特征的机器学习模型可预测晚期乳腺癌对T-DXd治疗的反应讲者：刘月平（河北医科大学第四医院）摘要号：10P 英文标题：A randomized phase 3 study of disitamab vedotin (DV) versus chemotherapy (chemo) in HER2-low advanced breast cancer: overall and the liver metastasis (BCLM) subgroup results 中文标题：维迪西妥单抗对比化疗治疗HER2低表达晚期乳腺癌的随机III期研究：总体及肝转移亚组结果讲者：王佳玉（中国医学科学院肿瘤医院）摘要号：19P 英文标题：Ribociclib plus endocrine therapy versus chemotherapy in patients with rapidly progressive HR+/HER2− advanced breast cancer: a multicenter phase II study with external controls 中文标题：瑞波西利联合内分泌治疗对比化疗用于快速进展HR+/HER2−晚期乳腺癌：一项多中心II期研究及外部对照讲者：Min Tian (Nanjing, China) 摘要号：26P 英文标题：Efficacy and Safety of Anlotinib-Based Therapy in Advanced Breast Cancer: A Real-World Study 中文标题：以安罗替尼为基础方案治疗晚期乳腺癌的真实世界疗效与安全性研究讲者：姚静（华中科技大学同济医学院附属协和医院）摘要号：27P 英文标题：Local treatment in metastatic breast cancer with oligoprogression: a retrospective cohort study and reconstructive individual patient data meta-analysis 中文标题：寡进展转移性乳腺癌的局部治疗：回顾性队列研究与重建个体患者数据荟萃分析讲者：Haoting Shi (Shanghai, China) 摘要号：73eP 英文标题：Chidamide combined with Vinorelbine and Capecitabine for HER2-Negative Advanced Breast Cancer: A Single-Arm, Single-Center, Phase II Clinical Trial 中文标题：西达本胺联合长春瑞滨和卡培他滨治疗HER2阴性晚期乳腺癌：一项单臂、单中心II期临床试验讲者：La Zou (Chongqing, China) 摘要号：74eP 英文标题：Intraventricular thiotepa in combination with methotrexate for leptomeningeal metastasis from breast cancer (NJMU-BC04): a single-arm phase II study 中文标题：脑室内注射塞替哌联合甲氨蝶呤治疗乳腺癌软脑膜转移（NJMU-BC04）：一项单臂II期研究讲者：Mengyao Zha (Nanjing, China) 摘要号：79eP 英文标题：Eribulin After Antibody-Drug Conjugate Treatment in Metastatic Breast Cancer: A Real-World Multicenter Retrospective Study 中文标题：抗体偶联药物治疗后应用艾立布林治疗转移性乳腺癌：一项真实世界多中心回顾性研究讲者：邵彬（北京大学肿瘤医院）摘要号：83eP 英文标题：An EGFR dominating triple positive tumor clone engages cycling M2 macrophages during disease progression following bispecific HER3/EGFR antibody-drug conjugate (ADC) treatment in metastatic breast cancer 中文标题：EGFR主导的三阳性肿瘤克隆在转移性乳腺癌双特异性HER3/EGFR ADC治疗后疾病进展中招募循环M2巨噬细胞讲者：吕铮（吉林大学第一医院）摘要号：96eP 英文标题：Real-world effectiveness of antibody-drug conjugates versus conventional systemic therapies in metastatic breast cancer: An inverse probability of treatment weighting analysis 抗体偶联药物对比传统全身治疗在转移性乳腺癌中的真实世界疗效：逆概率处理加权分析讲者：Shukai Guo (Fuzhou, China) Breast cancer, early stage（早期乳腺癌）摘要号：547P 英文标题：Predictive Role of ctDNA for Pseudoprogression in Triple-Negative Breast Cancer during Neoadjuvant Immunotherapy 中文标题：ctDNA在三阴性乳腺癌新辅助免疫治疗期间假性进展的预测作用讲者：王永胜（山东省肿瘤医院）摘要号：560P 英文标题：Efficacy and Safety of Pyrotinib Combined with Trastuzumab and Aromatase Inhibitor in Neoadjuvant Treatment of HER2+/HR+ Breast Cancer: A Single-Arm, Multi-Center Phase II Exploratory Study 中文标题：吡咯替尼联合曲妥珠单抗和芳香化酶抑制剂新辅助治疗HR+/HER2+乳腺癌：一项单臂、多中心II期探索性研究讲者：葛洁（天津医科大学肿瘤医院）摘要号：570P 英文标题：Qualitative synergism between female hormone use and secondhand smoke on breast carcinogenesis: A prospective cohort study 中文标题：雌激素使用与二手烟在乳腺癌发生中的定性协同作用：一项前瞻性队列研究讲者：Hong-Hong Zhu (Quzhou, China) 摘要号：580P 英文标题：Ki-67-Guided Stratification and Resistance Mechanism Analysis of CDK4/6 Inhibitor Therapy Following Adaptive Neoadjuvant Endocrine Treatment in HR+/HER2− Breast Cancer 中文标题：HR+/HER2-乳腺癌中适应性新辅助内分泌治疗后CDK4/6抑制剂治疗的Ki-67引导分层与耐药机制分析讲者：王永胜（山东省肿瘤医院）摘要号：616eP 英文标题：Radiotherapy-Integrated Neoadjuvant Therapy Deepens Response and Expands Eligibility for Surgery Omission in TNBC and HR-/HER2+ Breast Cancer: Interim Analysis of a Multicenter Phase II Study 中文标题：放疗联合新辅助治疗可增强对TNBC和HR-/HER2+乳腺癌的疗效，并扩大免手术治疗发适应证：一项多中心II期研究期中分析讲者：杨正军（天津医科大学肿瘤医院）摘要号：617eP 英文标题：Ultrasound-Guided Vacuum-Assisted Excision Followed by Definitive Surgery in Early-Stage Small Breast Cancer: A Single-Arm Trial 中文标题：超声引导下真空辅助旋切术后续根治性手术治疗早期小乳腺癌：一项单臂试验讲者：Siyuan Wang (Xi'an, China) 摘要号：628eP 英文标题：Extended Sentinel Lymph Node Biopsy Using a Single Tracer After Neoadjuvant Therapy for Breast Cancer: A Retrospective Real-World Study 中文标题：乳腺癌新辅助治疗后应用单一示踪剂的扩展前哨淋巴结活检：一项回顾性真实世界研究讲者：张聚良（空军军医大学西京医院）摘要号：635eP 英文标题：Profound Vitamin D Deficiency Identifies Elevated Heart Failure Risk Among Breast Cancer Survivors: A UK Biobank Multi-State Analysis 中文标题：重度维生素D缺乏识别乳腺癌幸存者中升高的心力衰竭风险：一项UK Biobank多状态分析讲者：Yiyin Zhang (Beijing, China) 摘要号：636eP 英文标题：A novel single-molecule dual CDK4/CDK2 inhibitor series with cytotoxic cellular activity and improved kinome selectivity for HR+/HER2− breast cancer and CCNE1-amplified ovarian cancer 中文标题：新型单分子双靶点CDK4/CDK2抑制剂系列：针对HR+/HER2−乳腺癌和CCNE1扩增卵巢癌具有细胞毒活性和改善的激酶组选择性讲者：Xianqiang Sun (Shanghai, China) 摘要号：639eP 英文标题：Carbon Nano-Lymph Tracer in Modified Radical Mastectomy After Neoadjuvant Chemotherapy for Breast Cancer 中文标题：纳米碳淋巴示踪剂在乳腺癌新辅助化疗后改良根治术中的应用讲者：Feng Liu (Fuyang, China, Anhui) 摘要号：646eP 英文标题：Patient and Oncologist Preferences Regarding CDK4/6 Inhibitor Adjuvant Therapy for HR+/HER2- Early Breast Cancer in China 中文标题：中国HR+/HER2−早期乳腺癌患者与肿瘤科医生对CDK4/6抑制剂辅助治疗的偏好讲者：郝春芳（天津医科大学肿瘤医院）摘要号：648eP 英文标题：Standard imaging-guided, Doppler-free chest wall perforator flap reconstruction for granulomatous lobular mastitis: A simplified approach for resource-limited settings 中文标题：标准影像引导下，无多普勒胸壁穿支皮瓣重建术治疗肉芽肿性小叶性乳腺炎：面向资源有限地区的简化方案讲者：王子莹（常州市第一人民医院） HER2+ breast cancer（HER2阳性乳腺癌）摘要号：1772P 英文标题：A Study Evaluating the Safety and Efficacy of Pyrotinib Dose Escalation Plus Loperamide Prophylaxis in First-Line Treatment of Advanced HER2-Positive Breast Cancer 中文标题：一项评估吡咯替尼剂量递增联合洛哌丁胺预防HER2阳性晚期乳腺癌一线治疗中安全性与有效性的研究讲者：晁腾飞（华中科技大学同济医学院附属同济医院）摘要号：1773P 英文标题：Neoadjuvant Oral Paclitaxel Plus Subcutaneous Fixed-Dose Pertuzumab/Trastuzumab in Stage II-III HER2+ Breast Cancer: First-Stage Results from a Simon's Two-Stage Study 中文标题：口服紫杉醇联合皮下注射固定剂量帕妥珠单抗/曲妥珠单抗新辅助治疗II-III期HER2+乳腺癌：Simon两阶段设计第一阶段结果讲者：Yudong Li (Guangzhou, China) 摘要号：1775P 英文标题：Dalpiciclib plus Pyrotinib-Based Chemotherapy-Free Regimens as first line treatment in Trastuzumab-Sensitive, HER2-Positive Metastatic Breast Cancer (DAP-HER-02): A Dual-Cohort, Phase II Study 中文标题：达尔西利联合吡咯替尼无化疗方案一线治疗曲妥珠单抗敏感的HER2阳性转移性乳腺癌（DAP-HER-02）：一项双队列II期研究讲者：牛李敏（郑州大学第一附属医院）摘要号：1776P 英文标题：IBI354 plus pertuzumab as first-line (1L) treatment for patients with HER2-positive, unresectable locally advanced or metastatic breast cancer: Results from a phase 2 study 中文标题：IBI354联合帕妥珠单抗一线治疗HER2阳性不可切除局部晚期或转移性乳腺癌：一项II期研究结果讲者：曾晓华（重庆大学附属肿瘤医院）摘要号：1778P 英文标题：Updated results of SHR-A1811 plus pertuzumab in human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic breast cancer: a phase 1b/2 study 中文标题：SHR-A1811联合帕妥珠单抗治疗HER2阳性不可切除/转移性乳腺癌的更新结果：一项Ib/II期研究讲者：黄香（南京医科大学第一附属医院）摘要号：1779P 英文标题：Prognostic Impact of PIK3CA Mutations in HER2-Positive Advanced Breast Cancer: A Real-World Multicenter Study 中文标题：PIK3CA突变对HER2阳性晚期乳腺癌的预后影响：一项真实世界多中心研究讲者：王瓯晨（温州医科大学附属第一医院）摘要号：1781P 英文标题：Real-World Comparative Study of Pertuzumab- vs Pyrotinib-Based First-Line Regimens in HER2-Positive Advanced Breast Cancer: A Xinjiang Multicenter Study 中文标题：帕妥珠单抗对比吡咯替尼一线治疗HER2阳性晚期乳腺癌的真实世界比较：一项新疆多中心研究讲者：赵兵（新疆医科大学附属肿瘤医院）摘要号：1802eP 英文标题：Neoadjuvant Chemotherapy plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer: A Prospective, Single-arm, Multi-center Study (NEOTORCH-BREAST05) 中文标题：新辅助化疗联合吡咯替尼和曲妥珠单抗治疗HER2阳性乳腺癌：一项前瞻性、单臂、多中心研究（NEOTORCH-BREAST05）讲者：Zhijun Dai (Hangzhou, China) 摘要号：1803eP 英文标题：Multicenter, phase II study of eribulin, carboplatin, trastuzumab and pertuzumab as neoadjuvant therapy in HER2-positive early or locally advanced breast cancer 中文标题：艾立布林、卡铂、曲妥珠单抗和帕妥珠单抗新辅助治疗HER2阳性早期或局部晚期乳腺癌的多中心II期研究讲者：Di Lu (Chengdu, China) 摘要号：1810eP 英文标题：Inetetamab Combined with Pyrotinib for HER2-Positive Advanced Breast Cancer: A Multicenter Real-World Retrospective Study 中文标题：伊尼妥单抗联合吡咯替尼治疗HER2阳性晚期乳腺癌：一项多中心真实世界回顾性研究讲者：Zenggui Wu (Taizhou, China) 摘要号：1812eP 英文标题：Enhanced protein lactylation accompanies acquired resistance to trastuzumab deruxtecan in HER2-positive breast cancer 中文标题：增强的蛋白乳酰化伴随HER2阳性乳腺癌对德曲妥珠单抗的获得性耐药讲者：Nan Jin (Nanjing, China) 摘要号：1814eP 英文标题：Antibody-programmable MOFs reshape multi-dimensional intervention strategies for programmed cell death in HER2+ breast cancer 中文标题：抗体可编程金属有机框架重塑HER2+乳腺癌程序性细胞死亡的多维干预策略讲者：王宇（首都医科大学附属北京同仁医院）摘要号：1818eP 英文标题：Characterization of Antibody Drug Conjugate-Associated Interstitial Lung Disease in Breast Cancer: A Systematic Review and Meta-Analysis 中文标题：乳腺癌抗体偶联药物相关间质性肺病的特征：系统综述与荟萃分析讲者：Yinuo Dong (Beijing, China) 摘要号：1823eP 英文标题：Ranking of First-Line Treatments for Advanced HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis 中文标题：HER2阳性晚期乳腺癌一线治疗的排序：贝叶斯网络荟萃分析讲者：Yuxin Sun (Beijing, China) 摘要号：1828eP 英文标题：Breast Ultrasound for Early Prediction of Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Real-World Analysis 中文标题：乳腺超声用于HER2阳性乳腺癌新辅助治疗疗效早期预测的真实世界分析讲者：Yuhang Xiao (Nanjing, China) 摘要号：1838eP 英文标题：FAP Expression Heterogeneity Drives Efficacy Variation of Targeted Radioligand Therapy and Patient Selection in HER2-Positive Breast Cancer 中文标题：FAP表达异质性驱动HER2阳性乳腺癌靶向放射性配体治疗的疗效差异与患者筛选讲者：Ting Wu (Luzhou, China) 摘要号：1841eTiP 英文标题：Al18F-HER2-BCH PET/CT guided precision neoadjuvant therapy for HER2-positive early breast cancer: FHERNAT trial 中文标题：Al18F-HER2-BCH PET/CT引导的HER2阳性早期乳腺癌精准新辅助治疗：FHERNAT试验讲者：梁旭（北京大学肿瘤医院） HR+ breast cancer（激素受体阳性乳腺癌）摘要号：1847P 英文标题：SHR-A2102, a Nectin-4-directed antibody drug conjugate (ADC), in pretreated HR+/HER2- advanced breast cancer: results from a phase 1 study 中文标题：SHR-A2102（靶向Nectin-4的ADC）用于经治HR+/HER2−晚期乳腺癌：一项I期研究结果讲者：闫敏（郑州大学附属肿瘤医院）摘要号：1848P 英文标题：First-in-human study of JYP0035, a highly selective PI3Kα inhibitor, as monotherapy in patients with advanced solid tumors 中文标题：高选择性PI3Kα抑制剂JYP0035单药治疗晚期实体瘤的首次人体研究讲者：孟艳春（复旦大学附属肿瘤医院）摘要号：1849P 英文标题：A Phase 1b/2 Study of JS105 in Combination with Dalpiciclib and Fulvestrant in Patients with Advanced Breast Cancer 中文标题：JS105联合达尔西利和氟维司群治疗晚期乳腺癌的Ib/II期研究讲者：闫敏（郑州大学附属肿瘤医院）摘要号：1852P 英文标题：Evaluation of the safety and efficacy of SH3765 in combination with fulvestrant in HR+/HER2− advanced breast cancer: a phase Ib study 中文标题：SH3765联合氟维司群治疗HR+/HER2−晚期乳腺癌的安全性与疗效评估：一项Ib期研究讲者：潘跃银（中国科学技术大学附属第一医院）摘要号：1858P 英文标题：BL0175 Injection for Locally Advanced/Metastatic HR+/HER2− Breast Cancer: Preliminary Results from Dose Escalation Stage of a Phase 1 Study 中文标题：BL0175注射液治疗局部晚期/转移性HR+/HER2−乳腺癌：I期剂量递增阶段初步结果讲者：王楠娅（吉林大学第一医院）摘要号：1859P 英文标题：First-line fovinaciclib for advanced breast cancer: updated analysis of a randomized, double-blind phase 3 study 中文标题：伏维西利一线治疗晚期乳腺癌：随机双盲III期研究更新分析讲者：袁芃（中国医学科学院肿瘤医院）摘要号：1869P 英文标题：Lysine acetyltransferase 6A (KAT6A) for predicting tamoxifen resistance in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer 中文标题：赖氨酸乙酰转移酶6A预测HR+/HER2−早期乳腺癌他莫昔芬耐药讲者：Tan Yujing (Beijing, China) 摘要号：1881P 英文标题：Clinical outcomes of YL202/BNT326 (HER3 ADC) in advanced/metastatic HR+/HER2-null/low breast cancer in chemotherapy-naïve and exposed patients 中文标题：YL202/BNT326（HER3 ADC）在初治和经治晚期/转移性HR+/HER2零表达/低表达乳腺癌中的临床结局讲者：孟艳春（复旦大学附属肿瘤医院）摘要号：1886TiP 英文标题：A phase I/II study of GenSci145 as monotherapy or combination therapy in PIK3CA-mutated advanced solid tumors 中文标题：GenSci145单药或联合治疗PIK3CA突变晚期实体瘤的I/II期研究讲者：徐兵河（中国医学科学院肿瘤医院）摘要号：1890eP 英文标题：Integrated Molecular Profiling of Paired Tumor Tissue and Circulating Tumor DNA in Chinese Patients with HR+/HER2- Advanced Breast Cancer Prior to First-Line Systemic Therapy 中文标题：中国HR+/HER2−晚期乳腺癌患者一线全身治疗前配对肿瘤组织与循环肿瘤DNA的整合分子分型讲者：岳健（中国医学科学院肿瘤医院）摘要号：1892eP 英文标题：An Open-label, Single-arm Study of Dalpiciclib in Combination with Aromatase Inhibitor and Capecitabine as Neoadjuvant Therapy for high-risk HR+/HER2- Early Breast Cancer 中文标题：达尔西利联合芳香化酶抑制剂和卡培他滨新辅助治疗高危HR+/HER2−早期乳腺癌：一项开放标签、单臂研究讲者：韩忠华（福建医科大学附属协和医院）摘要号：1893eP 英文标题：Dalpiciclib combined with endocrine therapy and capecitabine in high-risk HR+/HER2- advanced breast cancer: a multicenter phase II study 中文标题：达尔西利联合内分泌治疗和卡培他滨治疗高危HR+/HER2−晚期乳腺癌：一项多中心II期研究讲者：张捷（福建医科大学附属协和医院）摘要号：1895eP 英文标题：Early Toxicity-Driven Dose Modification Preserves Efficacy of Adjuvant Abemaciclib in High-Risk HR+/HER2− Early Breast Cancer: A Real-World Study in Chinese Patients 中文标题：早期毒性驱动的剂量调整不影响高危HR+/HER2−早期乳腺癌辅助阿贝西利疗效：一项中国患者真实世界研究讲者：Jing Huang (Xi'an, China) 摘要号：1896eP 英文标题：Fruquintinib plus eribulin in patients with metastatic HR+, HER2- breast cancer after progression on endocrine therapy plus CDK4/6 inhibitor: Updated results from a phase II study 中文标题：呋喹替尼联合艾立布林治疗内分泌治疗联合CDK4/6抑制剂进展后的转移性HR+/HER2−乳腺癌：II期研究更新结果讲者：袁渊（南京医科大学第一附属医院）摘要号：1898eP 英文标题：Real-World Outcomes of First-Line CDK4/6 Inhibitors Plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer: A Large National Cohort Study in China 中文标题：CDK4/6抑制剂联合内分泌治疗一线治疗HR+/HER2−晚期乳腺癌的真实世界结局：中国大型全国性队列研究讲者：罗扬（中国医学科学院肿瘤医院）摘要号：1903eP 英文标题：Patient-reported outcomes after switching from goserelin implant to goserelin microsphere in breast cancer: preliminary results of a prospective study 中文标题：乳腺癌患者从戈舍瑞林植入剂转换为戈舍瑞林微球后的患者报告结局：一项前瞻性研究初步结果讲者：张蓝心（大连医科大学附属第二医院）摘要号：1904eP 英文标题：CPS-EG Combined With Postoperative Ki-67 Outperforms ypTNM for Prognostication in HR+/HER2- Breast Cancer After Neoadjuvant Therapy: An 801-Patient Single-Center Retrospective Cohort Study 中文标题：CPS-EG联合术后Ki-67对HR+/HER2−乳腺癌新辅助治疗后预后的预测价值优于ypTNM：一项801例患者单中心回顾性队列研究讲者：Tian Yi Zhou (Guangzhou, China) 摘要号：1907eP 英文标题：Real-World Effectiveness and Safety of the Novel Agent Inavolisib in Heavily Pretreated, PIK3CA-mut Advanced Breast Cancer: A Multicenter Study of Patients with More Advanced and Complex Disease 中文标题：伊那利塞在重度经治PIK3CA突变晚期乳腺癌中的真实世界疗效与安全性：一项针对病情更晚期复杂疾病患者的多中心研究讲者：梁旭（北京大学肿瘤医院）摘要号：1911eP 英文标题：Optimal sequencing of systemic therapies for HR+/HER2− advanced breast cancer stratified by visceral and liver metastases: a systematic review and network meta-analysis 中文标题：按内脏和肝转移分层HR+/HER2−晚期乳腺癌全身治疗的最佳序贯策略：系统综述与网络荟萃分析讲者：Hong Cheng (Beijing, China) 摘要号：1918eP 英文标题：ABC-RWS-01 interim analysis of elacestrant in Chinese ESR1-mutated ER+/HER2- advanced breast cancer 中文标题：Elacestrant治疗中国ESR1突变ER+/HER2−晚期乳腺癌的ABC-RWS-01研究期中分析讲者：Wenbo Shi (Qionghai, China) 摘要号：1923eP 英文标题：Real-World Effectiveness and Safety of Maintenance Endocrine Therapy With or Without CDK4/6 Inhibitors Following Chemotherapy in HR-Positive/HER2-Negative Advanced Breast Cancer 中文标题：HR+/HER2-晚期乳腺癌化疗后维持内分泌治疗联合或不联合CDK4/6抑制剂的真实世界疗效与安全性讲者：李慧慧（山东省肿瘤医院）摘要号：1929eP 英文标题：Characterization of PIK3CA variants and real-world clinical evolution of first-line CDK4/6 inhibitors: Insights from a Chinese HR+/HER2- advanced breast cancer cohort 中文标题：PIK3CA变异特征与一线CDK4/6抑制剂治疗的真实世界临床演变：来自中国HR+/HER2−晚期乳腺癌队列的见解讲者：石晶（中国医科大学附属第一医院）摘要号：1936eP 英文标题：Safety profile of exemestane vs. anastrozole in the real world: a disproportionality analysis of FAERS database and systematic review of case reports 中文标题：依西美坦对比阿那曲唑的真实世界安全性：FAERS数据库不相称性分析与病例报告系统综述讲者：Chunsu Liang (Beijing, China) 摘要号：1943eTiP 英文标题：SoGreat: A phase Ib modular study of sacituzumab govitecan plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer after progression on CDK4/6 inhibitors 中文标题：SoGreat：戈沙妥珠单抗联合内分泌治疗用于CDK4/6抑制剂进展后HR+/HER2-转移性乳腺癌的Ib期模块化研究讲者：Zhonghui Zheng (Shanghai, China) 摘要号：1944eTiP 英文标题：The NASA (Neoadjuvant Ribociclib plus Aromatase Inhibitor) Trial: A randomized comparison versus chemotherapy in HR+/HER2- EBC 中文标题：NASA试验（新辅助哌柏西利联合芳香化酶抑制剂）：HR+/HER2−早期乳腺癌中对比化疗的随机对照研究讲者：蔡子杰（中山大学孙逸仙纪念医院） Supportive care（支持治疗）摘要号：3950P 英文标题：Musculoskeletal pain, neutrophil recovery kinetics, and exploratory immune-profiling with telpegfilgrastim versus other long-acting G-CSFs in breast cancer: TELEGRAM 中文标题：乳腺癌中拓培非格司亭对比其他长效G-CSF的肌肉骨骼疼痛、中性粒细胞恢复动力学及探索性免疫分型：TELEGRAM研究讲者：李薇（南京医科大学第一附属医院）摘要号：4028eP 英文标题：Efficacy and safety of telpegfilgrastim in breast cancer patients undergoing (neo)adjuvant chemotherapy for prophylaxis of chemotherapy-induced neutropenia: A multicenter, prospective, observational study 中文标题：拓培非格司亭在乳腺癌（新）辅助化疗患者预防化疗所致中性粒细胞减少的疗效与安全性：一项多中心、前瞻性、观察性研究讲者：张少华（解放军总医院）摘要号：4057eP 英文标题：Prospective Cohort Study on the Prophylaxis of Catheter-related Thrombosis in Breast Cancer Patients 中文标题：乳腺癌患者导管相关血栓预防的前瞻性队列研究讲者：Shiyu Li (Beijing, China) 摘要号：4071eP 英文标题：Auricular point stimulation plus dexamethasone for nausea and vomiting caused by docetaxel combined with cyclophosphamide in breast cancer adjuvant chemotherapy (ADDC) 中文标题：耳穴刺激联合地塞米松用于乳腺癌辅助化疗多西他赛联合环磷酰胺所致恶心呕吐（ADDC研究）讲者：Juan Wang (Hangzhou, China) 摘要号：4138eP 英文标题：Physiological and Functional Responses to Ultrasound-Guided Dextrose Hydrodissection in Breast Cancer Survivors With Persistent Chest Wall and Axillary Tightness 中文标题：超声引导下葡萄糖水分离术对持续性胸壁和腋窝紧绷的乳腺癌幸存者的生理与功能反应讲者：Yuchun Lee（中国台湾台中市） Triple negative breast cancer（三阴性乳腺癌）摘要号：4651P 英文标题：Competing risk nomogram for cancer-specific mortality and risk-stratified treatment associations in women with T2N0M0 triple-negative breast cancer: a SEER study (2010-2016) 中文标题：T2N0M0三阴性乳腺癌患者癌症特异性死亡竞争风险列线图及风险分层治疗关联：一项SEER研究（2010-2016）讲者：Sirui Zhu (Beijing, China) 摘要号：4652P 英文标题：225Ac-PSMA-targeted alpha therapy (TRC003) in metastatic TNBC: A prospective, multicenter, single-arm safety/efficacy trial 中文标题：225Ac-PSMA靶向α核素治疗（TRC003）在转移性TNBC中的应用：一项前瞻性、多中心、单臂安全性与疗效试验讲者：孙晓蓉（山东第一医科大学附属肿瘤医院）摘要号：4653P 英文标题：A phase 2, multicenter, open-label study to evaluate the efficacy and safety of ATRA plus toripalimab and chemotherapy in patients with previously treated locally advanced or metastatic triple-negative breast cancer 中文标题：ATRA联合特瑞普利单抗和化疗治疗经治局部晚期或转移性三阴性乳腺癌的II期多中心开放标签研究讲者：陶中华（复旦大学附属肿瘤医院）摘要号：4655P 英文标题：Efficacy and Safety of First-Line Treatment for Advanced Triple-Negative Breast Cancer: A Network Meta-Analysis of Randomized Controlled Trials 中文标题：晚期三阴性乳腺癌一线治疗的疗效与安全性：随机对照试验网络荟萃分析讲者：Junxiao Wang (Fuzhou, China) 摘要号：4657P 英文标题：Subtyping-guided addition of bevacizumab to treatment of physician's choice for previously untreated, advanced, basal-like immune-suppressed triple-negative breast cancer (OASIS/BCTOP-T-M01): a randomised, multicentre, phase 3 trial 中文标题：分型指导的贝伐珠单抗联合医生选择方案治疗初治晚期基底样免疫抑制型三阴性乳腺癌（OASIS/BCTOP-T-M01）：一项随机、多中心III期试验讲者：马林晓曦（复旦大学附属肿瘤医院）摘要号：4678P 英文标题：The Efficacy and Safety of Utidelone Plus Tislelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) 中文标题：优替德隆联合替雷利珠单抗和贝伐珠单抗治疗晚期或转移性三阴性乳腺癌（UTILIZABLE研究）讲者：Qingxu Liu (Wuhan, China) 摘要号：4680eP 英文标题：Identification of angiogenesis-related diagnostic and prognostic gene signatures for triple-negative breast cancer via machine learning and single-cell analysis 中文标题：基于机器学习和单细胞分析鉴定三阴性乳腺癌血管生成相关诊断和预后基因特征讲者：Hanbo Wang (Tianjin, China) 摘要号：4682eP 英文标题：Isojacareubin induces apoptosis of chemoresistant-triple negative breast cancer by epigenetic repression of PIK3CA via deacetylation of Histone 3 lysine 56 中文标题：异山竹素通过组蛋白H3K56去乙酰化表观遗传抑制PIK3CA诱导化疗耐药三阴性乳腺癌凋亡讲者：Dar-Ren Chen（中国台湾彰化市）摘要号：4686eP 英文标题：Single-cell transcriptomics reveals drivers of tumor microenvironment reprogramming and immunotherapy resistance in triple-negative breast cancer 中文标题：单细胞转录组学揭示三阴性乳腺癌肿瘤微环境重编程和免疫治疗耐药的驱动因素讲者：Shuangqi Qian (Tianjin, China) 摘要号：4690eP 英文标题：Association of PCSK9 Inhibitor Use With Breast Cancer Survival and Recurrence: A Target Trial Emulation 中文标题：PCSK9抑制剂使用与乳腺癌生存和复发的关联：目标试验模拟讲者：Salida Ali（中国香港）摘要号：4693eP 英文标题：PD-1 Inhibitor Sintilimab Concurrent with Epirubicin, Cyclophosphamide, and Nab-Paclitaxel as Neoadjuvant Therapy for Triple-Negative Breast Cancer: A Single-Arm, Phase II Study 中文标题：PD-1抑制剂信迪利单抗联合表柔比星、环磷酰胺和白蛋白紫杉醇新辅助治疗三阴性乳腺癌：一项单臂II期研究讲者：Duanyang Zhai (Guangzhou, China) 摘要号：4695eP 英文标题：Carboplatin plus taxanes combined with or without PD-1 inhibitors as neoadjuvant therapy in triple-negative breast cancer: A Propensity-Matched Cohort Study 中文标题：卡铂联合紫杉类联合或不联合PD-1抑制剂新辅助治疗三阴性乳腺癌：一项倾向性匹配队列研究讲者：Hongwei Lyu (Beijing, China) 摘要号：4700eP 英文标题：Radiological Complete Response as a Predictor of Neoadjuvant Therapy Efficacy in Early Triple-Negative Breast Cancer: A Multicenter Real-World Study 中文标题：影像学完全缓解作为早期三阴性乳腺癌新辅助治疗疗效的预测因素：一项多中心真实世界研究讲者：Wenyu Yang (Beijing, China) 摘要号：4702eP 英文标题：A Tumor Cell Membrane-Based FTY720 Nanoplatform Synergizes with [177Lu]Lu Radionuclide Therapy for Triple-Negative Breast Cancer 中文标题：基于肿瘤细胞膜的FTY720纳米平台协同[177Lu]Lu放射性核素治疗三阴性乳腺癌讲者：Yuyue Hou (Wuhan, China) 摘要号：4724eP 英文标题：Predictive value of tertiary lymphoid structures for immunotherapy efficacy in triple-negative breast cancer 讲者：三级淋巴结构对三阴性乳腺癌免疫治疗疗效的预测价值讲者：刘月平（河北医科大学第四医院）摘要号：4732eP 英文标题：Landscape of Peripheral Immune Response Induced by Multimodal Thermal Therapy Combined with Chemoimmunotherapy in Patients with Early-stage Triple-negative Breast Cancer 中文标题：多模式热疗联合化学免疫治疗诱导早期三阴性乳腺癌患者外周免疫应答的全景分析讲者：Fei Lin Qu (Shanghai, China) AI for clinical workflows and decision-making（人工智能辅助临床工作流程与决策）摘要号：208P 英文标题：Multimodal Unified Survival Ensemble (MUSE) Predicts Immunotherapy Survival Benefit in Triple-negative Breast Cancer (TNBC): Analysis from the TORCHLIGHT Study 中文标题：多模态统一生存集成模型预测三阴性乳腺癌免疫治疗生存获益：TORCHLIGHT研究分析讲者：江泽飞（解放军总医院） AI for diagnostics and profiling (pathology, radiology, molecular biology)（人工智能辅助诊断与分子分型）摘要号：300P 英文标题：BRIGHT: a breast pathology foundation model for biomarker prediction and treatment stratification in breast cancer 中文标题：BRIGHT：用于乳腺癌生物标志物预测与治疗分层的基础病理模型讲者：刘芳芳（天津医科大学肿瘤医院）摘要号：314P 英文标题：Study on the association between HER2 expression in breast cancer and spatial heterogeneity of microvascular density 中文标题：乳腺癌HER2表达与微血管密度空间异质性的关联研究讲者：Jingyue Li (Shenyang, China) 摘要号：331P 英文标题：An Interpretable Whole-slide Image Framework for Automated Trop-2 H-score Assessment in Breast Cancer 中文标题：可解释的全玻片图像框架用于乳腺癌Trop-2 H-score自动评估讲者：刘月平（河北医科大学第四医院）摘要号：355P 英文标题：A Multimodal Model Integrating Therapeutic Response Patterns and AI-Powered Pathology for Survival Prediction in Breast Cancer After Neoadjuvant Therapy 中文标题：整合治疗反应模式与人工智能病理的多模态模型用于乳腺癌新辅助治疗后生存预测讲者：刘月平（河北医科大学第四医院） Developmental therapeutics（药物研发）摘要号：1119eP 英文标题：Nitazoxanide Induces Ferroptosis in Triple-Negative Breast Cancer by Dual Reprogramming of Iron Metabolism and the β-catenin/GPX4 Axis 中文标题：硝唑尼特通过双重重编程铁代谢和β-catenin/GPX4轴诱导三阴性乳腺癌铁死亡讲者：Tao He (Luzhou, China) Psycho-oncology（心理肿瘤学）摘要号：3495eP 英文标题：Machine Learning Models for Depression Risk Prediction in Breast Cancer Patients: A Cross-Sectional Study Based on the NHANES Database 中文标题：基于NHANES数据库的机器学习模型预测乳腺癌患者抑郁风险：一项横断面研究讲者：Junxiao Wang (Fuzhou, China) Translational research and biomarkers（转化研究与生物标志物）摘要号：4587eP 英文标题：Temperature-Responsive PDDNFs@QDs Integrating Simplified Isolation for Efficient Exosome Analysis Enables Breast Cancer Diagnosis and Subtyping 中文标题：温敏型PDDNFs@QDs整合简化分离实现高效外泌体分析用于乳腺癌诊断与分型讲者：Xiangyue Meng (Chengdu, China) （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

抗体药物偶联物临床2期临床结果

2026-07-20

·ioncology

ESMO 2026丨瞭望前瞻，50余项中国妇科肿瘤研究亮相ESMO，一文速览

编者按 2026年欧洲肿瘤内科学会（ESMO）年会于10月23日至27日在西班牙马德里盛大举办。作为全球肿瘤领域极具影响力的顶级学术盛会，年会汇聚了全球顶尖肿瘤临床专家、科研学者及医药行业从业者，集中展示肿瘤领域前沿基础研究与临床转化成果，引领全球肿瘤诊疗技术发展方向。本次大会妇科肿瘤赛道硕果颇丰，多位中国专家携重磅研究成果亮相，涵盖宫颈癌、卵巢癌、子宫内膜癌等常见妇科恶性肿瘤的靶向治疗、免疫治疗、联合放化疗、真实世界研究及多组学机制探索等多个热门方向，充分展现了中国妇科肿瘤领域的科研实力与临床创新水平。本文系统整理本次ESMO年会收录的中国专家口头报告、壁报研究成果，以期为行业学术交流与临床研究参考提供翔实资料。 ✦ 快速口头报告摘要号：1240RO 英文标题：Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase 3 trial中文标题：艾帕洛利托沃瑞利单抗（QL1706）联合化疗±贝伐珠单抗一线治疗持续性、复发性或转移性宫颈癌：一项双盲、随机、安慰剂对照Ⅲ期临床试验结果讲者：刘继红教授中山大学肿瘤防治中心摘要号：1243RO 英文标题：JSKN033, a first-in-class subcutaneous (SC)-injected fixed-dose combination (FDC) of biparatopic anti-HER2 ADC and PD-L1 inhibitor, in pre-treated cervical cancer中文标题：全球首创皮下注射双表位抗HER2 ADC联合PD-L1抑制剂固定复方制剂JSKN033用于经治宫颈癌的临床研究讲者：吴小华教授复旦大学附属肿瘤医院妇瘤科摘要号：1244RO 英文标题：SHR-A2102, a novel nectin-4-targeted antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: results from a phase 2 study中文标题：新型Nectin-4靶向抗体药物偶联物SHR-A2102治疗复发/转移性宫颈癌Ⅱ期临床研究结果讲者：刘继红教授中山大学肿瘤防治中心 ✦ 壁报+电子壁报摘要号：1348eP 英文标题：Association of location of BRCA1/BRCA2 mutations and benefit from PARP inhibitor maintenance in ovarian cancer: a systemic review中文标题：卵巢癌BRCA1/BRCA2突变位点与PARP抑制剂维持治疗获益相关性的系统综述讲者：Ming Wang (Beijing, China) 摘要号：1359eP 英文标题：Role of BTLA in Ovarian Cancer and Its Clinical Prognostic Significance Based on Multi-Omics Analysis.中文标题：基于多组学分析BTLA在卵巢癌中的作用及其临床预后价值讲者：Yiliminuer Abulajiang (Beijing, China) 摘要号：1362eP 英文标题：Multi-omics provide insights into the effect of neoadjuvant chemotherapy on the tumor microenvironment in cervical cancer中文标题：多组学解析新辅助化疗对宫颈癌肿瘤微环境的调控作用讲者：Silu Meng (Wuhan, China) 摘要号：1365eP 英文标题：Updated Efficacy and Safety Data of First-Line Anlotinib + Carboplatin/Paclitaxel Induction Followed by Anlotinib Maintenance in Advanced Ovarian Cancer: Phase II Multicenter Trial (ALTER-GO-010)中文标题：安罗替尼联合卡铂/紫杉醇诱导后安罗替尼维持一线治疗晚期卵巢癌多中心Ⅱ期研究（ALTER-GO-010）更新疗效与安全性数据讲者：Wenjun Cheng (Nanjing, China) 摘要号：1367eP 英文标题：CD8+/FOXP3+ Tumor-Infiltrating Lymphocytes and Systemic Immune-Inflammation Index revealed as a Predictor to Neoadjuvant Cadonilimab Plus Chemotherapy in Advanced Ovarian Cancer from the Phase II CANECT Trial中文标题：Ⅱ期CANECT研究证实CD8+/FOXP3+肿瘤浸润淋巴细胞与全身免疫炎症指数可预测卡度尼利单抗联合化疗新辅助治疗晚期卵巢癌疗效讲者：Jie Tang (Changsha, China) 摘要号：1368eP 英文标题：Clinical Practice Patterns of HER2 Testing and Treatment in Endometrial Cancer in China: A Cross-Sectional Survey中文标题：中国子宫内膜癌HER2检测与治疗临床实践现状横断面调查讲者：Jihong Liu (Guangzhou, China) 摘要号：1371eP 英文标题：Hyperthermic Intraperitoneal Treatment to Enhance the Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Ovarian Cancer: Stage 1 Results of a Phase II Trial (HIPET-IO) (NCT07068178)中文标题：腹腔温热治疗提升晚期卵巢癌免疫检查点抑制剂疗效：Ⅱ期HIPET-IO研究（NCT07068178）I阶段结果讲者：Hui Li (Guangzhou, China) 摘要号：1379eP 英文标题：Safety, Immunogenicity, and Efficacy of RG002, an mRNA-LNP-Based Therapeutic Targeting HPV 16/18 E2/E6/E7, in Patients with CIN2/3: Results from a Phase I and Expanded Clinical Study中文标题：靶向HPV16/18 E2/E6/E7的 mRNA-LNP 治疗疫苗RG002用于CIN2/3患者的安全性、免疫原性及疗效I期及扩展临床研究结果讲者：Shan Cen (Beijing, China) 摘要号：1382eP 英文标题：Study on the Comparison between Fangzhi Decoction and Kangfuxin in Preventing Gastrointestinal Toxicity Induced by Concurrent Chemoradiotherapy for Cervical Cancer中文标题：防芷汤与康复新液预防宫颈癌同步放化疗所致胃肠道毒性对比研究讲者：Shengfa Su (Guiyang, China) 摘要号：1386eP 英文标题：Exploratory study of TP53 mutations in circulating tumor DNA as prognostic and longitudinal monitoring biomarkers for relapsed ovarian carcinoma patients中文标题：循环肿瘤DNA TP53突变作为复发性卵巢癌预后及动态监测生物标志物探索研究讲者：Zheng Feng (Shanghai, China) 摘要号：1388eP 英文标题：Rapid Histopathological Regression of CIN2 with APL-1702 Photodynamic Therapy: Preliminary Findings from a Multicenter Study中文标题：APL-1702光动力治疗实现CIN2快速组织病理学缓解：一项多中心研究初步结果讲者：Yu Zhang (Changsha, China) 摘要号：1394eP 英文标题：Intimate Partner Violence-Related Stress Accelerates Cervical Cancer Development via a Brain–Cholinergic Nerve–Tumor Axis中文标题：亲密伴侣暴力相关应激通过脑-胆碱能神经-肿瘤轴促进宫颈癌进展讲者：Jingrui Jiang (Wuhan, China) 摘要号：1395eP 英文标题：Association of Silva Pattern C with Lymph Node Metastasis Count and Prognosis in Cervical Adenocarcinoma After Radical Hysterectomy : Construction of a Nomogram Prediction Model.中文标题：宫颈腺癌根治术后Silva C型与淋巴结转移数目及预后相关性：列线图预测模型构建讲者：Jiehui Li (Guiyang, China) 摘要号：1396eP 英文标题：Clinical landscape of oncolytic virotherapy in gynecologic malignancies中文标题：溶瘤病毒疗法在妇科恶性肿瘤中的临床应用全景讲者：Kaiyu Fu (Chengdu, China) 摘要号：1403eP 英文标题：RBP4 orchestrates metabolic reprogramming of ovarian cancer and the omentum microenvironment for cancer dissemination中文标题：RBP4调控卵巢癌及大网膜微环境代谢重编程促进肿瘤播散讲者：Weiao Qu (Tianjin, China) 摘要号：1405eP 英文标题：Single-cell RNA sequencing reveals the important role of intercommunication between epithelial cells and cancer-associated fibroblasts in the peritoneal metastasis of high-grade serous ovarian cancer中文标题：单细胞RNA测序揭示上皮细胞与癌相关成纤维细胞互作在高级别浆液性卵巢癌腹膜转移中的关键作用讲者：Xiaoting Zhao (Beijing, China) 摘要号：1406eP 英文标题：Therapy-selected primitive hematopoietic clones in PARP inhibitor–associated t-MN: longitudinal single-cell insights from ovarian cancer中文标题：PARP抑制剂相关治疗相关髓系肿瘤中经药物筛选的原始造血克隆：卵巢癌患者纵向单细胞研究讲者：Yuanqiong Duan (Chengdu, China) 摘要号：1407eP 英文标题：HPV18 is a poor prognostic factor in patients with small cell neuroendocrine cervical cancer.中文标题：HPV18是宫颈小细胞神经内分泌癌不良预后因素讲者：Chyong-Huey Lai (Taoyuan City, Taiwan) 摘要号：1412eP 英文标题：Anxiety-driven sympathetic nerve–CAF–NGF axis promotes ovarian cancer progression and immune evasion中文标题：焦虑介导交感神经-癌相关成纤维细胞-NGF轴促进卵巢癌进展与免疫逃逸讲者：Yueming Zhang (Suzhou, China) 摘要号：1416eP 英文标题：Clinical Characteristics Analysis of a Single-Cell and Spatial Transcriptomics Cohort Treated with Zimberelimab Combined with Chemoradiotherapy for Intermediate- and Advanced-Stage Cervical Cancer中文标题：基于单细胞及空间转录组队列分析Zimberelimab联合放化疗治疗中晚期宫颈癌的临床特征讲者：Yunyan Zhang (Harbin, China) 摘要号：1420eP 英文标题：Epidemiology and Treatment Options for Cervical Cancer Patients Aged ≤25 Years based on SEER database and Real world research中文标题：基于SEER数据库与真实世界研究的25岁及以下宫颈癌患者流行病学特征及治疗方案分析讲者：Chen Ji (Beijing, China) 摘要号：1425eP 英文标题：Real-world outcomes of FRα targeting treatment with MIRV in Chinese PROC patients中文标题：MIRV靶向叶酸受体α治疗中国铂耐药卵巢癌患者真实世界疗效讲者：Jing Li (Shanghai, China) 摘要号：1426eP 英文标题：Correlation Between Recurrence Patterns and Clinical Risk Factors Following Prophylactic Irradiation of the the Inguinal Lymphatic Drainage Area in Stage IIIA Cervical Cancer中文标题：IIIA期宫颈癌腹股沟淋巴引流区预防性放疗后复发模式与临床危险因素相关性讲者：Fenghu Li (Guiyang, China) 摘要号：1427eP 英文标题：Clinical Characteristics and Treatment Strategy Analysis of 21 Cervical Cancer Patients Undergoing Hysterectomy After Radical Radiotherapy中文标题：21例根治性放疗后接受子宫切除术宫颈癌患者临床特征与治疗策略分析讲者：Zhuoying Du (Beijing, China) 摘要号：1428eP 英文标题：Neoadjuvant Iparomlimab and Tuvonralimab (PD-1/CTLA-4 Bifunctional Antibody) Plus Chemotherapy Enables Radical Surgery in Locally Advanced Cervical Cancer中文标题：PD-1/CTLA-4双特异性抗体艾帕洛利托沃瑞利单抗新辅助化疗可实现局部晚期宫颈癌根治性手术讲者：Wei Sheng (Jinan, China) 摘要号：1430eP 英文标题：Reduced-Dose Dexamethasone (Dex) Plus Netupitant/Palonosetron (NEPA) for Prevention of Nausea and Vomiting in Cervical Cancer Patients Undergoing Concurrent Chemoradiotherapy（CCRT）: An Interim Analysis中文标题：减量地塞米松联合奈妥匹坦/帕洛诺司琼预防宫颈癌同步放化疗恶心呕吐中期分析讲者：Re Yang (Guiyang, China) 摘要号：1440eP 英文标题：MEOX2 promotes the survival and dissemination of ovarian cancer cells via the activation of UPR under nutrient stress中文标题：营养应激下MEOX2通过激活未折叠蛋白反应促进卵巢癌细胞存活与播散讲者：Rui Zhou (Tianjin, China) 摘要号：1441eTiP 英文标题：Prospective Single-Arm Exploratory Study of Disitamab Vedotin Combination Regimen as Neoadjuvant Therapy for HER2-Expressing Ovarian Cancer中文标题：维迪西妥单抗联合方案用于HER2表达卵巢癌新辅助治疗前瞻性单臂探索研究讲者：Jing X. Tong (Shenyang, China) 摘要号：1253P 英文标题：Biparatopic Anti-HER2 Antibody Drug Conjugate (ADC) JSKN003 in Platinum-Resistant Ovarian Cancer (PROC): updated Overall Survival (OS) Analysis from Two Early-Phase Studies After Median Follow-Up (mFU) of 20.5 Months中文标题：双表位抗HER2 ADC药物JSKN003治疗铂耐药卵巢癌：两项早期研究中位随访20.5个月更新总生存数据讲者：Xiaohua Wu (Shanghai, China) 摘要号：1254P 英文标题：Disitamab Vedotin (RC48)-based Therapy in Heavily Prior Treated Patients with Recurrent Ovarian Cancer: A Real-World Multicenter Study中文标题：基于维迪西妥单抗（RC48）方案治疗多线经治复发性卵巢癌多中心真实世界研究讲者：Lei Yuan (Shanghai, China) 摘要号：1255P 英文标题：Elfetabart drozuntecan (Elfe-D; DB-1311/BNT324 [B7H3 ADC]) in patients with platinum-resistant ovarian cancer (PROC): Efficacy and safety data from a Phase 2 dose optimization cohort中文标题：B7H3 ADC药物 Elfetabart drozuntecan（DB-1311/BNT324）治疗铂耐药卵巢癌Ⅱ期剂量优化队列疗效与安全性数据讲者：Jianqing Zhu (Hangzhou, China) 摘要号：1259P 英文标题：Sacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) in Post-Platinum Advanced Mismatch Repair Proficient (pMMR) Endometrial Cancer (EC): Results From a Phase 2 Study (2870-002/SKB264-II-06)中文标题：芦康沙妥珠单抗联合帕博利珠单抗治疗铂耐药晚期错配修复完整子宫内膜癌Ⅱ期研究结果（2870-002/SKB264-II-06）讲者：Xiaohua Wu (Shanghai, China) 摘要号：1260P 英文标题：Updated Progression-Free Survival (PFS) Results from the FLAMES Study: First-Line Maintenance Senaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (aOC)中文标题：FLAMES研究更新无进展生存数据：塞那帕利一线维持治疗初诊晚期卵巢癌讲者：Xiaohua Wu (Shanghai, China) 摘要号：1265P 英文标题：3-year survival outcomes of image-guided radiotherapy combined with nimotuzumab for elderly patients with locally advanced cervical squamous cell carcinoma: a multi-center phase 2 trial中文标题：图像引导放疗联合尼妥珠单抗治疗老年局部晚期宫颈鳞癌3年生存结局多中心Ⅱ期研究讲者：Ang Qu (Beijing, China) 摘要号：1271P 英文标题：Efficacy and Safety of MSLN-Specific Autologous CAR-T Cell Therapy in Patients with Recurrent Ovarian Cancer: An Investigator-Initiated Single-Arm Clinical Trial中文标题：间皮素靶向自体CAR-T细胞治疗复发性卵巢癌疗效与安全性：一项研究者发起单臂临床试验讲者：Guohui Qin (Zhengzhou, China) 摘要号：1276P 英文标题：Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and definitive radiotherapy as first-line treatment for oligometastatic cervical cancer: a single-arm, phase II study中文标题：艾帕洛利托沃瑞利单抗（QL1706）化疗同步根治性放疗一线治疗寡转移宫颈癌单臂Ⅱ期研究讲者：Jing Liu (Jinan, China) 摘要号：1277P 英文标题：Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab induced concurrent chemoradiotherapy for high-risk locally advanced cervical cancer: A Prospective, Single-Arm Phase II Clinical Trial中文标题：艾帕洛利托沃瑞利单抗（QL1706）±贝伐珠单抗化疗诱导同步放化疗治疗高危局部晚期宫颈癌前瞻性单臂Ⅱ期临床研究讲者：Xiao'juan Lv (Hangzhou, China) 摘要号：1280P 英文标题：Long Term Follow-up Results from a Phase I/II Study of Nilvanstomig (ZG005), a Bispecific Antibody Targeting PD-1 and TIGIT, as Monotherapy in Patients with Advanced Cervical Cancer中文标题：PD-1/TIGIT双特异性抗体 Nilvanstomig（ZG005）单药治疗晚期宫颈癌I/Ⅱ期长期随访结果讲者：Shuxia Cheng (Zhengzhou, China) 摘要号：1282P 英文标题：Phase I/II Study of Nilvanstomig (ZG005) Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment for Advanced Cervical Cancer: Updated Results of Efficacy and Safety中文标题：PD-1/TIGIT双特异性抗体 Nilvanstomig（ZG005）联合化疗±贝伐珠单抗一线治疗晚期宫颈癌 I/Ⅱ期更新疗效与安全性数据讲者：Hanmei Lou (Hangzhou, China) 摘要号：1283P 英文标题：Phase II Study of Fruquintinib Plus Utidelone in Platinum-Resistant Recurrent Ovarian Cancer (FRUTD Trial)中文标题：呋喹替尼联合优替德隆治疗铂耐药复发性卵巢癌Ⅱ期FRUTD临床研究讲者：Zheng Feng (Shanghai, China) 摘要号：1289P 英文标题：Subtype-Specific Outcomes and Risk-Adapted Treatment Patterns in Endometrial Stromal Sarcoma: A 214-Patient Retrospective Cohort中文标题：子宫内膜间质肉瘤各亚型生存结局及风险分层治疗模式：214例患者回顾性队列研究讲者：Lingcong Yang (Fuzhou, China) 摘要号：1297P 英文标题：Preliminary outcomes of a phase II study of the highly potent PI3K/mTOR dual inhibitor WX390 monotherapy in patients with platinum-resistant ovarian clear cell carcinoma harboring PIK3CA mutations中文标题：高选择性PI3K/mTOR双靶点抑制剂WX390单药治疗伴PIK3CA突变铂耐药卵巢透明细胞癌Ⅱ期初步结果讲者：Jiajia Li (Shanghai, China) 摘要号：1301P 英文标题：A real-world study of patients with gastric-type adenocarcinoma of the cervix中文标题：宫颈胃型腺癌患者真实世界临床研究讲者：Mengting Che (Chengdu, China) 摘要号：1303P 英文标题：Efficacy of Iparomlimab and Tuvonralimab (QL1706) in Cervical Cancer: A Multicenter, Prospective, Real-World Study中文标题：艾帕洛利托沃瑞利单抗（QL1706）治疗宫颈癌多中心前瞻性真实世界疗效研究讲者：Yan Lu (Nantong, China) 摘要号：1315P 英文标题：Redefining risk in cervical cancer: a novel histology-site subtype framework uncovers high- Risk adenocarcinoma through risk reversal中文标题：宫颈癌风险分层再定义：全新组织 - 解剖分型体系通过风险反转识别高危腺癌亚型讲者：Xiaolian Peng (Dongguan, China) 摘要号：1326P 英文标题：Induction Weekly Chemoimmunotherapy with Enlonstobart as a Priming Approach to De-escalated Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer中文标题：恩朗苏拜单抗周疗化疗免疫诱导方案用于局部晚期宫颈癌降阶梯同步放化疗预处理讲者：Ai Huang (Wuhan, China) 摘要号：1327P 英文标题：Longitudinal Changes of Systemic Tumoe Immune Envoriment (STIE) in Cervical Cancer Patients Receiving Radiotherapy中文标题：接受放疗的宫颈癌患者全身肿瘤免疫微环境纵向动态变化规律讲者：Caining Zhao (Shenzhen, China) （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

2026-07-18

·QQ浏览器

肿瘤治疗皮下制剂「靠谱」吗？带你解读皮下制剂的四大误区！

引言肿瘤治疗领域长期以来高度依赖静脉（IV）给药。靶向、免疫治疗相关生物制剂多为大分子单抗，给药剂量高，几乎均经 IV 输入患者体内，也便于医疗机构监控输注相关反应（IRR）。然而，IV 给药对需长期治疗的患者负担沉重。反复往返医院、长时间滞留输液，不仅严重影响患者时间精力与生活质量，亦大量消耗医疗资源，构成了肿瘤治疗中不可忽视的成本要素。在这一背景下，皮下（SC）给药正逐渐成为重要的替代给药途径。近年来，帕博利珠单抗、纳武利尤单抗、阿替利珠单抗等多款免疫单抗皮下制剂相继在欧美获批上市；在中国，阿替利珠单抗皮下注射剂于 2025 年 11 月获中国国药药品监督管理局（NMPA）批准上市，特瑞普利单抗皮下注射剂也已进入上市申报阶段，意味着我国肿瘤免疫治疗也正迈入「皮下注射时代」。然而，关于 SC 给药在肿瘤治疗中的价值，临床实践中仍存在诸多疑虑：SC 给药的疼痛与体积限制、免疫原性风险、生物利用度不确定性、临床桥接的复杂性等，这些问题在一定程度上制约了皮下制剂在肿瘤领域的更广泛应用。对此，本文中「丁香园肿瘤时间」基于前沿研究和临床综述，重新审视这四大问题，以循证证据回应临床关切。❌ 误区一：SC 给药疼痛感强，且仅限小体积给药抗肿瘤生物制剂给药多为高剂量，例如帕博利珠单抗静脉标准剂量为 200 mg 每 3 周一次或 400 mg 每 6 周一次，纳武利尤单抗固定剂量为 240 mg 每 2 周一次或 480 mg 每 4 周一次，若改用皮下注射，给药体积通常超过 3-5 mL。而传统 2 mL 自动注射器无法实现高剂量给药；另一方面，肿瘤医生和患者同样担心：大体积皮下注射是否增加了注射的疼痛感？注射部位组织能否耐受？这均限制了肿瘤治疗中皮下给药的应用[1]。循证证据这一顾虑正在被越来越多的临床数据所消解。目前，药物递送技术的进步已支持首批高容量（≥5 mL）单克隆抗体皮下注射剂（如曲妥珠单抗注射液）获得全球多地区药品管理部门批准上市[2]，突破了皮下大容量给药的技术难题。此外，大容量皮下给药的耐受性已得到充分验证。Dang 等人的研究显示，腹部区域注射体积高达 25 mL 时，受试者对肿胀、注射部位反应、针头插入和注射持续时间等方面的痛苦评分均较低[3]。Kang 等人的研究则采用透明质酸酶联合手持式高容量自动注射器，在约 30 秒内皮下注射 10 mL 溶液，大部分受试者报告无疼痛或仅有轻度疼痛[4]。更重要的是，肿瘤治疗领域已有部分单克隆抗体皮下注射剂的临床数据提供了直接证据：帕博利珠单抗 III 期 MK-3475A-D77 研究显示，SC 组中位注射给药时间仅为 2 分钟，注射部位反应发生率较低（2.4%），且严重程度较轻[5]；埃万妥单抗 PALOMA-3 研究中，SC 组首次给药中位时间仅 4.8 分钟，且注射部位疼痛、肿胀或发红达到中重度以上的患者比例分别仅为 14%、5% 和 5%[6]；纳武利尤单抗 CheckMate-67T 研究中，SC 组患者注射部位反应发生率约为 8%，且多为轻度、一过性轻[7]。上述研究均提示，患者对大容量 SC 给药具有良好耐受性，注射部位疼痛感受低于预期。❌ 误区二：SC 给药增加免疫原性免疫原性是抗肿瘤单克隆抗体临床应用中备受关注的问题之一，患者体内抗药物抗体（ADA）可能影响药物暴露量、疗效甚至安全性。传统观念认为，SC 给药因药物在注射部位滞留时间较长，更易接触抗原提呈细胞，其免疫原性风险或显著高于 IV 给药。在肿瘤免疫治疗时代，若 SC 给药诱导患者体内产生更多的 ADA，进而削弱程序性死亡受体 / 配体 -1（PD-1/PD-L1）抑制剂的抗肿瘤活性，将带来严重的临床隐患。循证证据然而，日益丰富的循证医学证据正在重塑这一认知。多项系统性综述表明，治疗药物本身的分子特性对免疫原性的影响远大于给药途径。两项分别针对 17 种及 23 种同时具备 IV 和 SC 给药制剂的治疗性蛋白及生物制剂相关综述分析均证实，统一药物的两种给药途径 ADA 发生率总体相当，SC 给药并未表现出必然的免疫原性增加[8-9]。而在肿瘤治疗领域，MK-3475A-D77 研究中，SC 组和 IV 组患者体内 ADA 检出率分别为 1.4% 和 0.9%，差异极小[4]；IMscin001 研究中，阿替利珠单抗 SC 与 IV 给药的抗体发生率组间亦未达统计学显著性差异（19.5% vs 13.9%）[10]。此外，曲妥珠单抗、阿替利珠单抗等部分药物皮下注射剂 ADA 水平略有升高，仍显示出可接受的安全性和有效性，并获得美国国家食品药品监督管理局（FDA）批准上市[9]。❌ 误区三：SC 给药生物利用度低和 / 或暴露量不可预测肿瘤治疗追求精准给药，药物暴露量的稳定性和可预测性至关重要。SC 给药的生物利用度低于 100%（平均约 71±12%），部分单抗甚至低于 50% [11-12]。肿瘤医生自然会质疑：SC 给药能否提供与 IV 给药相当的、稳定可预测的药物暴露？这种暴露水平的差异是否会影响抗肿瘤疗效？循证证据针对这一问题目前已有多项 III 期研究展开，所有已获批的肿瘤皮下制剂均通过严格的药代动力学（PK）非劣效性研究证明了 SC 给药与 IV 给药在药物暴露量上的相当性。具体而言：帕博利珠单抗（MK-3475A-D77 研究）：SC 组（790 mg，每 6 周）与 IV 组（400 mg，每 6 周）相比，第 1 周期 AUC₀₋₆周的几何均值比值为 1.14，稳态谷浓度比值为 1.67，均达到非劣效性标准。在疗效终点上，SC 组和 IV 组获益同样相当，两组客观缓解率（ORR）分别为 45.4% vs 42.1%，无进展生存期（PFS）分别为 8.1 个月 vs 7.8 个月[5]。埃万妥单抗（PALOMA-3 研究）：SC 组与 IV 组给药后谷浓度比值为 1.15-1.42，第 2 周期 AUC 比值为 1.03，均达到非劣效性终点。值得注意的是，疗效方面，SC 组患者中位 PFS 在数值上优于 IV 组（6.1 个月 vs 4.3 个月，HR=0.84），总生存期显著延长（HR 0.62，95% CI：0.42-0.92，名义P=0.02）[6]。纳武利尤单抗（CheckMate-67T 研究）：SC 组患者给药 28 天平均血清浓度和稳态谷浓度均达到非劣效性主要终点，ORR 方面 SC 组为 24%，数值上甚至略优于 IV 组的 18%[7]。阿替利珠单抗（IMscin001 研究）：SC 组（1875 mg，每3周）与 IV 组（1200 mg，每 3 周）相比，第 1 周期药物暴露达到非劣效性标准，ORR 分别为 12% 和 10%，PFS HR 为 1.08[8]。达雷妥尤单抗（COLUMBA 研究）：与 IV 组相比，SC 组患者在 ORR 和药代动力学上均达到非劣效性主要终点[13]。艾沙妥昔单抗（IRAKLIA 研究）：SC 组（通过体表给药系统）与 IV 组的 ORR 分别为 71.1% 和 70.5%，12 个月 PFS 率分别为 66.1% 和 65.1%[14]。以上研究均表明：抗肿瘤单克隆抗体 SC 给药虽然绝对生物利用度低于 100%，但通过合理的剂量调整（通常剂量高于 IV 剂量），均可以实现与 IV 给药相当的稳态药物暴露水平，并在此基础上获得一致的抗肿瘤疗效。❌ 误区四：SC 给药制剂疗效尚不明确从已经确立的 IV 给药方案桥接至 SC 制剂，是否仍需要开展大规模的疗效验证性临床试验，同样是临床医生和患者共同关心的问题。循证证据事实上，从 IV 到 SC 给药的临床桥接策略已经相当成熟，肿瘤领域的相关临床实践充分验证了该策略的科学性与可行性。例如，帕博利珠单抗皮下制剂仅凭在转移性非小细胞肺癌中开展的 III 期药代动力学非劣效性研究（MK-3475A-D77 研究），即获 FDA 批准用于该药物静脉制剂多种已获批的实体瘤适应证。同样，纳武利尤单抗与阿替利珠单抗皮下注射剂也分别获批用于涵盖黑色素瘤、肾细胞癌、非小细胞肺癌等在内的多种实体瘤及其 IV 制剂所获批的所有成人适应证。上述案例表明，一旦药代动力学桥接研究证实 SC 给药与 IV 给药在药物暴露量上具有非劣效性，即可依托 IV 制剂既往积累的庞大疗效与安全性数据库，豁免重复的大规模疗效验证试验，大幅缩短皮下制剂的研发与上市周期，使患者更早获益。此外，相关临床证据还提示，部分药物在 SC 给药后，不仅输注相关反应的发生率更低，甚至在生存获益上展现出优于 IV 给药的潜力。这表明 SC 给药不仅是 IV 途径的便捷替代方案，在特定临床场景下更有望成为优选治疗策略。总结对于肿瘤患者而言，抗肿瘤治疗皮下制剂的问世不仅代表着给药方式的更迭，更是治疗体验与生活质量的飞跃。它成功将传统的「住院输液」转化为灵活的「门诊注射」，把漫长的「数小时」等待压缩「数分钟」，让患者得以从繁复的治疗流程中解脱，更好地回归正常生活。与此同时，对于医疗系统而言，这一剂型革新有效释放了输液中心的资源瓶颈，大幅提升了诊疗效率，并推动了整体医疗成本的优化。随着帕博利珠单抗、纳武利尤单抗、阿替利珠单抗等重磅免疫治疗药物皮下制剂的相继获批，以及特瑞普利单抗等国产创新制剂的加速推进，肿瘤治疗正迈入「皮下时代」。在循证医学的坚实支撑下，皮下给药正以「更便捷、更高效、更经济」的姿态切实转化为患者的生存获益。肿瘤治疗皮下注射，未来已来。参考文献[1] Bittner B, Buist N, Bruin G, et al. Challenging the myths of subcutaneous delivery: An industry expert perspective. J Control Release. 2026 Jun16;396:114902. [2] Herceptin® (trastuzumab) [Summary of product charateristics], European Medicines Agency, 2025 (Accessed February 9, 2026).[3] Dang X, Shih H, Sharma R, et al, Thyagarajapuram NR, Shi GH, Collins DS. Clinical Investigation of Large Volume Subcutaneous Delivery up to 25 mL for Lean and Non-Lean Subjects. Pharm Res. 2024 Apr;41(4):751-763.[4] Kang DW, Connor RJ, Nekoroski T,et al. A phase I clinical study to evaluate rapid, high-volume, subcutaneous auto-injector tolerability with recombinant human hyaluronidase. Drug Deliv Transl Res. 2026 Jan;16(1):95-107.[5] Felip E, Rojas CI, Schenker M, et al. Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Ann Oncol.2025 Jul;36(7):775-785.[6] Leighl NB, Akamatsu H, Lim SM, et al.Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. J Clin Oncol. 2024 Oct 20;42(30):3593-3605.[7] https://doi.org/10.1016/j.annonc.2024.09.002[8]J. Felderman, L. Ramaiah, M.D. Vazquez-Abad, D. Messing, Y. Chen, Anti-drug antibody incidence comparison of therapeutic proteins administered via subcutaneous vs. intravenous route, AAPS J. 26 (3) (2024) 60.[9] J.D. Davis, M. Bravo Padros, D.J. Conrado, S. Ganguly, X. Guan, H.E. Hassan, et al., Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development, Clin. Pharmacol. Ther. 115 (3) (2024) 422–439.[10]Burotto M, Zvirbule Z, Mochalova A, et al.IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications. Ann Oncol. 2023 Aug;34(8):693-702. doi: 10.1016/j.annonc.2023.05.009. Epub 2023 Jun 1. Erratum in: Ann Oncol. 2024 May;35(5):482. [11]K.P. Martin, C. Grimaldi, R. Grempler, S. Hansel, S. Kumar, Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics, MAbs 15 (1) (2023) 2191301.[12] Athe Tsibris, Yu E. Zheng, Edmund Capparelli, Katherine Rodriguez, Randall Tressler, Antoine Deslandes, et al. (Eds.), A First-in-Human Study of the Trispecific HIV-1 Broadly Neutralizing Antibody, SAR441236. Conference on Retroviruses and Opportunistic Infections, 2024. Denver, Colorado.[13] S.Z. Usmani, H. Nahi, W. Legiec, S. Grosicki, V. Vorobyev, I. Spicka, et al., Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma, Haematologica 107 (10) (2022) 2408–2417.[14] S. Ailawadhi, I. Spicka, A. Spencer, J. Lu, A. Oriol, S. Ling, et al., Isatuximab subcutaneous by on-body injector versus isatuximab intravenous plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: phase III IRAKLIA study, J. Clin. Oncol. 43 (22) (2025) 2527–2537.整理：暖暖；编辑：gulu题图：图虫创意

上市批准临床3期免疫疗法

100 项与地塞米松磷酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00975	地塞米松磷酸钠	D07AB19 H02AB02 D10AA03	DB01234

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脑水肿	奥地利	Hameln pharma Gmbh.	2021-04-28
脑水肿	比利时	Hameln pharma Gmbh.	2021-04-28
脑水肿	保加利亚	Hameln pharma Gmbh.	2021-04-28
脑水肿	克罗地亚	Hameln pharma Gmbh.	2021-04-28
脑水肿	捷克	Hameln pharma Gmbh.	2021-04-28
脑水肿	丹麦	Hameln pharma Gmbh.	2021-04-28
脑水肿	芬兰	Hameln pharma Gmbh.	2021-04-28
脑水肿	德国	Hameln pharma Gmbh.	2021-04-28
脑水肿	匈牙利	Hameln pharma Gmbh.	2021-04-28
脑水肿	冰岛	Hameln pharma Gmbh.	2021-04-28
脑水肿	爱尔兰	Hameln pharma Gmbh.	2021-04-28
脑水肿	意大利	Hameln pharma Gmbh.	2021-04-28
脑水肿	荷兰	Hameln pharma Gmbh.	2021-04-28
脑水肿	挪威	Hameln pharma Gmbh.	2021-04-28
脑水肿	波兰	Hameln pharma Gmbh.	2021-04-28
脑水肿	葡萄牙	Hameln pharma Gmbh.	2021-04-28
脑水肿	罗马尼亚	Hameln pharma Gmbh.	2021-04-28
脑水肿	斯洛伐克	Hameln pharma Gmbh.	2021-04-28
脑水肿	斯洛文尼亚	Hameln pharma Gmbh.	2021-04-28
新型冠状病毒感染	奥地利	Hameln pharma Gmbh.	2021-04-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床3期	美国	TLC BioSciences	2019-11-26
膝关节炎	临床3期	美国	台湾微脂体股份有限公司	2019-11-26
膝关节炎	临床3期	澳大利亚	台湾微脂体股份有限公司	2019-11-26
膝关节炎	临床3期	澳大利亚	TLC BioSciences	2019-11-26
根性疼痛	临床3期	美国	Scilex Pharmaceuticals, Inc.	2017-12-08
神经根病	临床3期	美国	Scilex Pharmaceuticals, Inc.	2017-12-08
共济失调毛细血管扩张	临床3期	美国	Quince Therapeutics, Inc.	2017-03-02
共济失调毛细血管扩张	临床3期	澳大利亚	Quince Therapeutics, Inc.	2017-03-02
共济失调毛细血管扩张	临床3期	比利时	Quince Therapeutics, Inc.	2017-03-02
共济失调毛细血管扩张	临床3期	德国	Quince Therapeutics, Inc.	2017-03-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01862315 (CTgov)	临床2期	不可切除的肝内胆管癌	56	Research blood draws+dexamethasone+Gemcitabine+Floxuridine (FUDR)+oxaliplatin (No Prior Chemo or Responded/Stable With Prior Chemo)	淵憲鹽鏇壓醖願網遞鹹 = 選壓醖夢廠築淵網淵蓋衊鏇鹽淵襯鹹糧選積糧 (範淵構構構窪壓艱膚醖, 膚簾鹽製膚壓糧遞網製 ~ 選積淵壓鑰獵鑰餘選構) 更多	-	2026-07-01
				Research blood draws+dexamethasone+Gemcitabine+Floxuridine (FUDR)+oxaliplatin (Patients Who Have Failed Systemic Therapy)	製憲顧選鹽淵餘製製壓 = 積艱繭夢製醖積艱構繭膚簾觸積襯襯顧積艱醖 (製艱醖築夢網鏇艱顧壓, 衊鏇糧鹽積鑰淵襯膚顧 ~ 淵繭廠簾構齋糧襯製觸) 更多
NCT04251715 (HELIX-1, CTgov)	临床2期	不可切除的肝内胆管癌	5	Quality-of-Life Assessment+leucovorin+Dexamethasone+Floxuridine+Irinotecan+oxaliplatin	觸積鬱窪憲鬱膚鹹鹹糧 = 艱積積窪鹹製選簾夢衊選範壓壓餘觸艱鹽餘夢 (餘鑰獵鑰製醖齋襯壓齋, 觸觸醖製壓築窪鑰遞壓 ~ 壓蓋築觸窪廠膚鹹鬱鬱) 更多	-	2026-06-25
NCT05732532 (CTgov)	临床4期	头痛	120	Greater/lesser occipital nerve blocks+Lidocaine+Bupivacaine (Anesthetic Without Steroid Group)	窪壓廠糧壓選淵廠選艱(膚簾壓淵積窪構蓋繭夢) = 夢鬱鑰鬱艱齋觸蓋壓顧膚願簾觸衊夢蓋夢壓製 (餘觸憲襯積廠醖鏇鬱願, 2.2) 更多	-	2026-06-24
				Greater/lesser occipital nerve blocks+Dexamethasone+Lidocaine+Bupivacaine (Anesthetic With Dexamethasone Group)	窪壓廠糧壓選淵廠選艱(膚簾壓淵積窪構蓋繭夢) = 製憲網艱窪簾醖製膚顧膚願簾觸衊夢蓋夢壓製 (餘觸憲襯積廠醖鏇鬱願, 2.3) 更多
NCT03598426 (CTgov)	临床3期	超敏反应	90	Dexamethasone (Conventional)	遞簾鹽淵鹽鹽鹽憲壓築 = 艱膚鹹構鏇繭選艱鹹範鏇齋顧襯壓鹹簾顧憲膚 (網齋鬱餘夢廠獵齋淵廠, 憲淵鏇遞醖醖窪夢壓衊 ~ 觸顧選積獵築夢齋鏇鏇) 更多	-	2026-06-09
				Dexamethasone (Short-Course)	遞簾鹽淵鹽鹽鹽憲壓築 = 糧遞餘壓鬱衊夢構壓築鏇齋顧襯壓鹹簾顧憲膚 (網齋鬱餘夢廠獵齋淵廠, 壓繭鹽鏇鏇窪鹽構夢範 ~ 襯淵憲簾淵廠鑰壓繭壓) 更多
NCT06272383 (Pubmed \| Trials)	临床3期	哮吼	1,850	0.60 mg/kg dexamethasone	衊餘鏇淵築廠鏇選選蓋(簾獵遞鏇鹽壓鑰壓顧觸) = 蓋壓簾製壓簾願鬱艱遞鑰壓觸繭糧製鹽鏇廠鹽 (襯積顧糧壓觸齋夢壓鹹 )	积极	2026-06-05
				0.15 mg/kg dexamethasone	衊餘鏇淵築廠鏇選選蓋(簾獵遞鏇鹽壓鑰壓顧觸) = 膚壓蓋鑰顧簾蓋憲鹹範鑰壓觸繭糧製鹽鏇廠鹽 (襯積顧糧壓觸齋夢壓鹹 )
BelaDRd (ASCO2026)	临床1/2期	多发性骨髓瘤一线	36	Belantamab mafodotin+daratumumab+lenalidomide+dexamethasone	範願膚淵築繭蓋糧齋蓋(選遞顧鹽餘廠範繭鹹範) = 構積衊願膚壓製遞齋夢獵壓餘糧鏇夢壓窪築淵 (積簾艱淵淵鹹窪廠構願 ) 更多	积极	2026-05-29
NCT04799015 (CTgov)	临床4期	创伤后头痛	162	Metoclopramide 10mg+Dexamethasone (Dexamethasone)	壓繭齋憲鹹選選鑰廠鹽 = 鬱糧觸壓構齋憲積艱膚糧醖構齋壓廠鬱選鏇鏇 (糧選膚顧鏇鑰壓繭蓋簾, 繭膚夢衊糧衊鏇積艱構 ~ 淵艱壓鑰築網壓蓋選憲) 更多	-	2026-05-15
				Metoclopramide 10mg (Placebo)	壓繭齋憲鹹選選鑰廠鹽 = 膚遞鏇願鹹鑰願選鏇顧糧醖構齋壓廠鬱選鏇鏇 (糧選膚顧鏇鑰壓繭蓋簾, 範積簾簾鏇糧製範觸遞 ~ 顧製窪夢餘壓醖醖範繭) 更多
EHA2026	N/A	多发性骨髓瘤一线	1,384	RVD (bortezomib+ lenalidomide+ dexamethasone)	鬱餘淵顧餘衊夢築窪齋(窪鏇選夢襯觸鏇願艱艱) = 廠鑰簾窪遞獵糧夢構積膚鏇選積遞窪選鹹鹽觸 (餘範觸鹹壓遞築鏇選獵 ) 更多	积极	2026-05-12
EHA2026	N/A	多发性骨髓瘤一线	3,971	Cyclophosphamide+Bortezomib+Dexamethasone	製製齋鏇構製艱窪壓製(憲網網餘衊醖簾夢衊鹽) = 膚醖網遞膚鹹鹹齋鬱鑰憲獵鑰餘淵願憲製製齋 (夢衊網顧膚製醖獵鏇鏇 ) 更多	积极	2026-05-12
				Daratumumab+Lenalidomide+Dexamethasone	醖鹽齋鏇鹽壓鹹簾夢鏇(蓋鏇襯選壓選選繭鏇夢) = 構鬱餘遞觸顧製淵鹹壓製膚鹹製築淵構淵艱淵 (選蓋鏇糧顧壓範廠齋鑰 ) 更多
EHA2026	N/A	巨球蛋白血症 MYD88 mutation - L265P \| del-17p	34	RBBd therapy program	築壓淵積鏇襯鏇獵觸遞(齋窪鹽窪積構鏇鬱襯築) = 齋鏇積餘淵衊窪膚簾齋顧窪範餘鹽鏇簾遞製鏇 (襯糧艱壓膚衊範繭築衊 ) 更多	积极	2026-05-12